Global autoinjectors market valued at $1.08B in 2023, reached $1.40B in 2024, and is projected to grow at a robust 13.6%
The global autoinjector devices market is projected to to expand to a value of USD 3.02 billion by 2030 from USD 1.40 billion in 2024, with a significant CAGR of 13.6%. The autoinjector finished formulations market is projected to surge to a value of USD 134.27 billion by 2030 from USD 67.30 billion in 2024, growing at a CAGR of 12.2%.
The key factors driving the growth of the global autoinjectors market are the growing launch of technologically advanced autoinjector devices, rise in regulatory approvals for finish formulations in autoinjector format, and increased adoption of home-based therapies by patients.
The market for autoinjectors is consolidated, with key players strategizing to capture the majority of the market. Prominent players in the autoinjector devices market are SHL Medical AG (Switzerland), Ypsomed AG (Switzerland), Becton, Dickinson and Company (BD) (US), Recipharm AB (Sweden), West Pharmaceutical Services, Inc.(US), Phillips-Medisize (US), Halozyme, Inc.
(US), Owen Mumford Ltd. (UK), Gerresheimer AG (Germany) and among others. Some of the major market players for finished formulations covered in this chapter include Abbvie Inc.
(US), Eli Lilly and Company (US), Amgen Inc. (US), Novo Nordisk A/S (Denmark), Jonhson & Jonhson Services Inc.
(US), Sanofi (France), GSK plc (UK).
Download an Illustrative overview: http://www.marketsandmarkets.com/pdfdown…ign=paidpr
Ypsomed AG is one of the dominant players in the global autoinjector market. Ypsomed offers an extensive product portfolio of self-injection device systems and infusion systems.
The company’s strong focus on geographic presence and launch of patient-centric autoinjector products influence to dominant market share. Ypsomed generally focuses on employing inorganic and organic growth strategies to maintain its strong position in the market.
The company has alliances and supply agreements with a few of the leading drug manufacturers globally. For instance, in September 2023, Ypsomed and Novo Nordisk entered into a long-term supply agreement for an massive quantity of autoinjectors.
Becton, Dickinson and Company (BD) is one of the prominent players in the autoinjector devices market. BD offers diversified drug delivery systems.
The company’s dominant position in the market is due to its strong brand presence, innovative product offerings, and strategies adopted by the company, such as collaborations, partnerships, and agreements. Additionally, a strong focus on expanding the company’s presence in emerging markets is further likely to strengthen BD’s market position in the autoinjectors market.
Furthermore, BD leverages its extensive global distribution network worldwide. This includes partnerships with local distributors and direct sales channels.
Request Sample Pages: http://www.marketsandmarkets.com/request…ign=paidpr
Autoinjectors Market Dynamics:
Drivers:
* Benefits of autoinjectors in emergency medical care
* Increasing regulatory approvals for autoinjectors
* Availability of generics and biosimilars in autoinjectors
* Government support and favorable reimbursements
* Growing awareness and adoption of self-administration
Restraints:
* Alternative drug delivery modes and needle phobia
Opportunities:
* Patent expiry of biologics
* Increasing shift of therapy to home settings
Challenges:
* Development of autoinjectors for multiple drug viscosities
Get 10% Free Customization on this Report: http://www.marketsandmarkets.com/request…ign=paidpr
News From
MarketsandMarkets™
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w …
This email address is being protected from spambots. You need JavaScript enabled to view it.
